ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER
批准号:
6886322
负责人:
TOWIA A. LIBERMANN
金额:
$25.14万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-01 至 2006-03-31
关键词:
androgen receptorathymic mouseenzyme activitygel mobility shift assaygene induction /repressionhormone related neoplasm /cancerhuman tissuemalemitogen activated protein kinaseneoplasm /cancer geneticsneoplastic processneoplastic transformationoncoproteinsprostate neoplasmsprostate specific antigentranscription factor
中文摘要
描述:前列腺癌已成为老年人最常见的实体癌。
男人。虽然雄激素消融治疗、手术和放射治疗
对于治疗局部前列腺癌有效,目前尚无有效方法
可用于转移性雄激素非依赖性疾病患者的治疗。
雄激素非依赖性晚期前列腺癌预后不良反映
这在一定程度上是因为缺乏对肿瘤基本生物学的了解。特别是,
人们对触发这种转化的分子机制知之甚少。
从最初的雄激素依赖型癌症到雄激素非依赖型癌症。我们的目标是
了解一种新的前列腺上皮特异性转录的作用
转录因子PDEF(前列腺源性ETS因子)
前列腺癌中的因子/癌基因家族。PDEF表示为
正常人前列腺腔上皮细胞及其初步结果
表明PDEF在卵巢癌组织中的表达升高。
前列腺。PDEF作为一种强大的转录因子独立于雄激素发挥作用
PSA和PSMA启动子的增强子,两个用于
监测雄激素依赖和非雄激素依赖性前列腺癌。激活的地图
蛋白水解酶能显著增强PDEF介导的转录激活。PDEF还
与雄激素受体相互作用和协同作用,诱导
PSA基因。因此,我们的假设是PDEF绕过或激活了
雄激素受体,从而促进从最初的
雄激素依赖型前列腺癌转变为雄激素非依赖型癌症。我们
建议确定ETS家族中这一新成员在
前列腺癌的形成和发展以及使用这种新技术的可能性
因子作为另一种诊断工具和潜在的治疗靶点。因此,
具体目标是:
具体目标1:PDEF在前列腺癌的发生中起关键作用吗?
还是进步?
特定目的#2:PDEF是前列腺特异性PSA基因的关键调节因子吗
表情?
特定目标#3.PDEF活性能解释前列腺癌的转化吗
细胞对雄激素的非依赖性?由于ETS家族在中国的重要性
对各种组织和分化特异基因的调节,以及由于
ETS家族几个成员在不同人类中的直接意义
癌症,PDEF有望在前列腺上皮细胞中发挥作用
转化或前列腺癌进展。
英文摘要
DESCRIPTION: Prostate cancer has become the most common solid cancer in older
men. Although androgen ablation therapy, surgery and radiation therapy are
effective for the treatment of local prostate cancer, there is no effective
treatment available for patients with metastatic androgen-independent disease.
The poor prognosis for androgen-independent advanced prostate cancer reflects
in part the lack of knowledge about the tumor's basic biology. In particular,
very little is known about the molecular mechanisms that trigger the conversion
of an initially androgen-dependent cancer to androgen-independence. Our goal is
to understand the role of a novel prostate epithelium-specific transcription
factor, PDEF (Prostate Derived Ets Factor), a member of the Ets transcription
factor/oncogene family in human prostate cancer. PDEF is expressed in the
luminal epithelial cells of normal human prostate and preliminary results
indicate that PDEF expression is elevated in cancerous portions of the
prostate. PDEF acts independently of androgen as a strong transcriptional
enhancer of the PSA and PSMA promoter, two diagnostic markers used for
monitoring androgen-dependent and -independent prostate cancer. Activated MAP
kinases drastically enhance PDEF mediated transcriptional activation. PDEF also
interacts and cooperates with the androgen receptor in inducing expression of
the PSA gene. Thus, our hypothesis is that PDEF bypasses or activates the
androgen receptor and thereby contributes to the progression from an initially
androgen-dependent prostate cancer to an androgen-independent cancer. We
propose to determine the role of this novel member of the Ets family in
prostate cancer formation and progression and the possibility to use this new
factor as another diagnostic tool and as a potential therapeutic target. Thus,
the specific aims are:
Specific Aim #1. Does PDEF play a crucial role in prostate cancer development
or progression?
Specific Aim #2. Is PDEF a critical regulator of prostate-specific PSA gene
expression?
Specific Aim #3. Can PDEF activity explain the conversion of prostate cancer
cells to androgen-independence? Due to the importance of the Ets family in
regulation of various tissue- and differentiation-specific genes and due to the
direct implication of several members of the Ets family in various human
cancers, PDEF is expected to play a role in prostate epithelial cell
transformation or prostate cancer progression.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/onc.2012.89
发表时间:
2013-02-07
期刊:
Oncogene
影响因子:
8
作者:
[]
通讯作者:
Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer.
转移性肾细胞癌中白细胞介素 2 治疗反应的蛋白质组学鉴定。
DOI:
10.1016/j.juro.2007.09.016
发表时间:
2008
期刊:
The Journal of urology
影响因子:
--
作者:
[Jones,Jon, Otu,HasanH, Grall,Franck, Spentzos,Dimitrios, Can,Handan, Aivado,Manuel, Belldegrun,ArieS, Pantuck,AllanJ, Libermann,TowiaA]
通讯作者:
Libermann,TowiaA
DOI:
10.2174/156652412800619978
发表时间:
2012-06
期刊:
Current molecular medicine
影响因子:
2.5
作者:
[Tamura RE, de Vasconcellos JF, Sarkar D, Libermann TA, Fisher PB, Zerbini LF]
通讯作者:
Zerbini LF
DOI:
--
发表时间:
2003-05
期刊:
Cancer research
影响因子:
11.2
作者:
[L. Zerbini;Yihong Wang;Je-Yoel Cho;T. Libermann]
通讯作者:
L. Zerbini;Yihong Wang;Je-Yoel Cho;T. Libermann
Advancing the Understanding of Postoperative Delirium Mechanisms via Multi-Omics
-
批准号:9204773
-
项目类别:
-
资助金额:$60.25万
-
财政年份:2016
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
Advancing the Understanding of Postoperative Delirium Mechanisms via Multi-Omics
-
批准号:9402039
-
项目类别:
-
资助金额:$62.23万
-
财政年份:2016
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
Role of Axl in docetaxel resistance in prostate cancer
-
批准号:8880713
-
项目类别:
-
资助金额:$21.11万
-
财政年份:2015
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline
-
批准号:10585942
-
项目类别:
-
资助金额:$87.41万
-
财政年份:2015
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
Novel treatment strategies for enhancing sunitinib response in renal cell cancer
-
批准号:8524387
-
项目类别:
-
资助金额:$22.71万
-
财政年份:2013
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
Novel treatment strategies for enhancing sunitinib response in renal cell cancer
-
批准号:8651433
-
项目类别:
-
资助金额:$18.35万
-
财政年份:2013
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
NOVEL APPROACHES TO GENE PROFILING IN OVARIAN CANCER
-
批准号:6870870
-
项目类别:
-
资助金额:$14.62万
-
财政年份:2005
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
NOVEL APPROACHES TO GENE PROFILING IN OVARIAN CANCER
-
批准号:7060081
-
项目类别:
-
资助金额:$14.28万
-
财政年份:2005
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
CORE-- GENOMIC AND BIONFORMATICS SUPPORT
-
批准号:6946588
-
项目类别:
-
资助金额:$11.78万
-
财政年份:2004
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
Ese-1, a New Transcriptional Mediator of Inflammation
-
批准号:6511364
-
项目类别:
-
资助金额:$36.5万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER
-
批准号:6266267
-
项目类别:
-
资助金额:$28.73万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER
-
批准号:6633648
-
项目类别:
-
资助金额:$25.14万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
Ese-1, a New Transcriptional Mediator of Inflammation
-
批准号:6709419
-
项目类别:
-
资助金额:$34.0万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
Ese-1, a New Transcriptional Mediator of Inflammation
-
批准号:6873688
-
项目类别:
-
资助金额:$34.0万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
Ese-1, a New Transcriptional Mediator of Inflammation
-
批准号:6632335
-
项目类别:
-
资助金额:$34.0万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
Ese-1, a New Transcriptional Mediator of Inflammation
-
批准号:6321886
-
项目类别:
-
资助金额:$32.3万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
FUNCTIONS OF ELF-1 AND A NOVEL ETS FACTOR NERF IN B CELLS
-
批准号:6472778
-
项目类别:
-
资助金额:$27.95万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER
-
批准号:6514408
-
项目类别:
-
资助金额:$25.14万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER
-
批准号:6724785
-
项目类别:
-
资助金额:$25.14万
-
财政年份:2001
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
NIDDK BIOTECHNOLOGY CENTER
-
批准号:6230920
-
项目类别:
-
资助金额:$43.48万
-
财政年份:2000
-
负责人:TOWIA A. LIBERMANN
-
依托单位:
海外基金